{"success":true,"data":{"pressRelease":{"id":"11964","rtpr_id":"nPn1PsbKta","ticker":"ANAB","exchange":"NASDAQ","all_tickers":["ANAB","VNDA"],"title":"Vanda Pharmaceuticals announces the publication of \"Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis\" in NEJM Evidence","author":"PR Newswire","published_at":"2026-04-28T23:13:02.529Z","article_body":"Vanda Pharmaceuticals announces the publication of \"Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis\" in NEJM Evidence\n\nPR Newswire\n\nWASHINGTON, April 28, 2026\n\nWASHINGTON, April 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda)\n(Nasdaq: VNDA) today announced the publication of the original research\narticle titled \"Efficacy and Safety of Imsidolimab for Generalized Pustular\nPsoriasis\" in New England Journal of Medicine (NEJM) Evidence(1).\n\n(https://mma.prnewswire.com/media/2090054/VandaLogo_v1.html)\n\nThe findings of this pivotal phase III study are included in the Biologics\nLicense Application (BLA) for imsidolimab for the treatment of Generalized\nPustular Psoriasis (GPP), submitted to the U.S. Food and Drug Administration\n(FDA) with a target action date of December 12, 2026.\n\nReferences\n\n 1. Smieszek, S. et al. Efficacy and Safety of Imsidolimab for Generalized\nPustular Psoriasis. NEJM Evidence 5, (2026).\nAbout Imsidolimab\n\nImsidolimab is a fully humanized IgG4 monoclonal antibody that inhibits IL-36\nreceptor signaling and is being developed for GPP, a rare orphan indication.\nRegulatory and patent exclusivity for imsidolimab is expected to extend into\nthe late 2030s. Vanda holds an exclusive global license for the development\nand commercialization of imsidolimab from AnaptysBio (Nasdaq: ANAB).\n\nAbout Vanda Pharmaceuticals\n\nVanda is a leading global biopharmaceutical company focused on the development\nand commercialization of innovative therapies to address high unmet medical\nneeds and improve the lives of patients. For more on Vanda Pharmaceuticals\nInc., please visit www.vandapharma.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4675952-1&h=3804074135&u=http%3A%2F%2Fwww.vandapharma.com%2F&a=www.vandapharma.com)\nand follow us on X @vandapharma.\n\nCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS\n\nVarious statements in this press release, including, but not limited to\nstatements regarding the anticipated timing of the completion of the FDA's\nreview of the imsidolimab BLA; Vanda's plans to seek FDA approval of\nimsidolimab for the treatment of GPP; and the potential to extend regulatory\nand patent exclusivity for imsidolimab into the late 2030s, are\n\"forward-looking statements\" under the securities laws. All statements other\nthan statements of historical fact are statements that could be deemed\nforward-looking statements. Forward-looking statements are based upon current\nexpectations and assumptions that involve risks, changes in circumstances and\nuncertainties. Important factors that could cause actual results to differ\nmaterially from those reflected in Vanda's forward-looking statements include,\namong others, the FDA's ability to complete its review of, and reach a\ndecision with respect to, the imsidolimab BLA by December 12, 2026; Vanda's\nability to obtain FDA approval of imsidolimab for the treatment of GPP; and\nVanda's ability to satisfy the conditions necessary to extend regulatory and\npatent exclusivity for imsidolimab into the late 2030s. Therefore, no\nassurance can be given that the results or developments anticipated by Vanda\nwill be realized, or even if substantially realized, that they will have the\nexpected consequences to, or effects on, Vanda. Forward-looking statements in\nthis press release should be evaluated together with the various risks and\nuncertainties that affect Vanda's business and market, particularly those\nidentified in the \"Cautionary Note Regarding Forward-Looking Statements\",\n\"Risk Factors\" and \"Management's Discussion and Analysis of Financial\nCondition and Results of Operations\" sections of Vanda's most recent Annual\nReport on Form 10-K, as updated by Vanda's subsequent Quarterly Reports on\nForm 10-Q, Current Reports on Form 8-K and other filings with the U.S.\nSecurities and Exchange Commission, which are available at www.sec.gov\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4675952-1&h=3374656580&u=http%3A%2F%2Fwww.sec.gov%2F&a=www.sec.gov)\n.\n\nAll written and verbal forward-looking statements attributable to Vanda or any\nperson acting on its behalf are expressly qualified in their entirety by the\ncautionary statements contained or referred to herein. Vanda cautions\ninvestors not to rely too heavily on the forward-looking statements Vanda\nmakes or that are made on its behalf. The information in this press release is\nprovided only as of the date of this press release, and Vanda undertakes no\nobligation, and specifically declines any obligation, to update or revise\npublicly any forward-looking statements, whether as a result of new\ninformation, future events or otherwise, except as required by law.\n\nCorporate Contact:\nKevin Moran\nSenior Vice President, Chief Financial Officer and Treasurer\nVanda Pharmaceuticals Inc.\n202-734-3400\npr@vandapharma.com (mailto:pr@vandapharma.com)\n\nJim Golden / Jack Kelleher / Dan Moore\nCollected Strategies\nVANDA-CS@collectedstrategies.com (mailto:VANDA-CS@collectedstrategies.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-the-publication-of-efficacy-and-safety-of-imsidolimab-for-generalized-pustular-psoriasis-in-nejm-evidence-302756392.html\n(https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-the-publication-of-efficacy-and-safety-of-imsidolimab-for-generalized-pustular-psoriasis-in-nejm-evidence-302756392.html)\n\nSOURCE Vanda Pharmaceuticals Inc.\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2090054/VandaLogo_v1.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn1PsbKta","title":"Vanda Pharmaceuticals announces the publication of \"Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis\" in NEJM Evidence","author":"PR Newswire","ticker":"ANAB","created":"2026-04-28T23:13:02.529Z","tickers":["ANAB","VNDA"],"exchange":"NASDAQ","article_body":"Vanda Pharmaceuticals announces the publication of \"Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis\" in NEJM Evidence\n\nPR Newswire\n\nWASHINGTON, April 28, 2026\n\nWASHINGTON, April 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda)\n(Nasdaq: VNDA) today announced the publication of the original research\narticle titled \"Efficacy and Safety of Imsidolimab for Generalized Pustular\nPsoriasis\" in New England Journal of Medicine (NEJM) Evidence(1).\n\n(https://mma.prnewswire.com/media/2090054/VandaLogo_v1.html)\n\nThe findings of this pivotal phase III study are included in the Biologics\nLicense Application (BLA) for imsidolimab for the treatment of Generalized\nPustular Psoriasis (GPP), submitted to the U.S. Food and Drug Administration\n(FDA) with a target action date of December 12, 2026.\n\nReferences\n\n 1. Smieszek, S. et al. Efficacy and Safety of Imsidolimab for Generalized\nPustular Psoriasis. NEJM Evidence 5, (2026).\nAbout Imsidolimab\n\nImsidolimab is a fully humanized IgG4 monoclonal antibody that inhibits IL-36\nreceptor signaling and is being developed for GPP, a rare orphan indication.\nRegulatory and patent exclusivity for imsidolimab is expected to extend into\nthe late 2030s. Vanda holds an exclusive global license for the development\nand commercialization of imsidolimab from AnaptysBio (Nasdaq: ANAB).\n\nAbout Vanda Pharmaceuticals\n\nVanda is a leading global biopharmaceutical company focused on the development\nand commercialization of innovative therapies to address high unmet medical\nneeds and improve the lives of patients. For more on Vanda Pharmaceuticals\nInc., please visit www.vandapharma.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4675952-1&h=3804074135&u=http%3A%2F%2Fwww.vandapharma.com%2F&a=www.vandapharma.com)\nand follow us on X @vandapharma.\n\nCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS\n\nVarious statements in this press release, including, but not limited to\nstatements regarding the anticipated timing of the completion of the FDA's\nreview of the imsidolimab BLA; Vanda's plans to seek FDA approval of\nimsidolimab for the treatment of GPP; and the potential to extend regulatory\nand patent exclusivity for imsidolimab into the late 2030s, are\n\"forward-looking statements\" under the securities laws. All statements other\nthan statements of historical fact are statements that could be deemed\nforward-looking statements. Forward-looking statements are based upon current\nexpectations and assumptions that involve risks, changes in circumstances and\nuncertainties. Important factors that could cause actual results to differ\nmaterially from those reflected in Vanda's forward-looking statements include,\namong others, the FDA's ability to complete its review of, and reach a\ndecision with respect to, the imsidolimab BLA by December 12, 2026; Vanda's\nability to obtain FDA approval of imsidolimab for the treatment of GPP; and\nVanda's ability to satisfy the conditions necessary to extend regulatory and\npatent exclusivity for imsidolimab into the late 2030s. Therefore, no\nassurance can be given that the results or developments anticipated by Vanda\nwill be realized, or even if substantially realized, that they will have the\nexpected consequences to, or effects on, Vanda. Forward-looking statements in\nthis press release should be evaluated together with the various risks and\nuncertainties that affect Vanda's business and market, particularly those\nidentified in the \"Cautionary Note Regarding Forward-Looking Statements\",\n\"Risk Factors\" and \"Management's Discussion and Analysis of Financial\nCondition and Results of Operations\" sections of Vanda's most recent Annual\nReport on Form 10-K, as updated by Vanda's subsequent Quarterly Reports on\nForm 10-Q, Current Reports on Form 8-K and other filings with the U.S.\nSecurities and Exchange Commission, which are available at www.sec.gov\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4675952-1&h=3374656580&u=http%3A%2F%2Fwww.sec.gov%2F&a=www.sec.gov)\n.\n\nAll written and verbal forward-looking statements attributable to Vanda or any\nperson acting on its behalf are expressly qualified in their entirety by the\ncautionary statements contained or referred to herein. Vanda cautions\ninvestors not to rely too heavily on the forward-looking statements Vanda\nmakes or that are made on its behalf. The information in this press release is\nprovided only as of the date of this press release, and Vanda undertakes no\nobligation, and specifically declines any obligation, to update or revise\npublicly any forward-looking statements, whether as a result of new\ninformation, future events or otherwise, except as required by law.\n\nCorporate Contact:\nKevin Moran\nSenior Vice President, Chief Financial Officer and Treasurer\nVanda Pharmaceuticals Inc.\n202-734-3400\npr@vandapharma.com (mailto:pr@vandapharma.com)\n\nJim Golden / Jack Kelleher / Dan Moore\nCollected Strategies\nVANDA-CS@collectedstrategies.com (mailto:VANDA-CS@collectedstrategies.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-the-publication-of-efficacy-and-safety-of-imsidolimab-for-generalized-pustular-psoriasis-in-nejm-evidence-302756392.html\n(https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-the-publication-of-efficacy-and-safety-of-imsidolimab-for-generalized-pustular-psoriasis-in-nejm-evidence-302756392.html)\n\nSOURCE Vanda Pharmaceuticals Inc.\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2090054/VandaLogo_v1.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-04-28T23:13:02.586828686Z","server_sent_at_ms":1777417982586},"received_at":"2026-04-28T23:13:02.638Z","source_url":null},"analysis":{"id":"9285","press_release_id":"11964","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Partner Vanda Pharmaceuticals published the original research article titled \"Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis\" in NEJM Evidence.\n\nThe findings from this pivotal Phase 3 study are included in the Biologics License Application submitted to the FDA, which has a target action date of December 12, 2026.\n\nAnaptysBio holds the exclusive global license for imsidolimab and stands to benefit from the drug's validation and potential approval later this year.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"NEJM publication validates partner Vanda's BLA submission for ANAB-licensed asset Imsidolimab."},"keyFigures":{"drugName":"Imsidolimab","phaseOfTrial":"Phase III","customDimensions":{"journal":"NEJM Evidence","indication":"Generalized Pustular Psoriasis (GPP)","pdufa_date":"December 12, 2026"}},"quotedText":"","namedEntities":{"people":[{"name":"Kevin Moran","role":"Senior Vice President, Chief Financial Officer and Treasurer"}],"products":["Imsidolimab"],"companies":[{"name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","relationship":"partner / licensee"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Peer-reviewed publication of pivotal Phase 3 data in NEJM Evidence provides independent validation for Imsidolimab ahead of the December 2026 PDUFA date. While the data supports the BLA, this is a dissemination event rather than a new primary readout or approval decision."},"tickerRelevance":{"others":[{"ticker":"VNDA","relevance":"partner"}],"primary":"ANAB"},"globalImportance":30,"audienceRelevance":35,"eventTypeSecondary":["regulatory"],"importanceComponents":{"tickerTier":"mid-cap biotech","eventGravity":"peer-reviewed publication of known pivotal data","sectorWeight":"biotech","marketCapAdjustment":"moderate"}},"event_type":"clinical_trial","event_type_secondary":["regulatory"],"sentiment":"bullish","material_impact_score":3,"narrative":"Partner Vanda Pharmaceuticals published the original research article titled \"Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis\" in NEJM Evidence.\n\nThe findings from this pivotal Phase 3 study are included in the Biologics License Application submitted to the FDA, which has a target action date of December 12, 2026.\n\nAnaptysBio holds the exclusive global license for imsidolimab and stands to benefit from the drug's validation and potential approval later this year.","key_figures":{"drugName":"Imsidolimab","phaseOfTrial":"Phase III","customDimensions":{"journal":"NEJM Evidence","indication":"Generalized Pustular Psoriasis (GPP)","pdufa_date":"December 12, 2026"}},"named_entities":{"people":[{"name":"Kevin Moran","role":"Senior Vice President, Chief Financial Officer and Treasurer"}],"products":["Imsidolimab"],"companies":[{"name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","relationship":"partner / licensee"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:1fc968c3ac7f7ebb","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-04-29T00:33:24.407Z","global_importance":30,"audience_relevance":35,"importance_components":{"tickerTier":"mid-cap biotech","eventGravity":"peer-reviewed publication of known pivotal data","sectorWeight":"biotech","marketCapAdjustment":"moderate"}},"durationMs":36863,"modelName":"glm-4.7"}}